353 bytes added
, 11:41, 14 July 2016
{{Startups
|industry=Therapeutics
|website=cellmachines.net
|total_raised=700000
}}
We have developed a scalable, multipurpose system for production of human therapeutic proteins that provides us with a tremendous cost advantage. Our first product is factor IX for the treatment of hemophilia B. This is currently an underserved $1.4 billion market. ...